Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT04850625 Active, not recruiting - Breast Cancer Clinical Trials

Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine

Start date: January 15, 2020
Phase:
Study type: Observational

Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine

NCT ID: NCT04808765 Active, not recruiting - Breast Cancer Clinical Trials

Closed Incision Disposable Negative Pressure Wound Therapy in Immediate Postmastectomy Breast Reconstruction

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

The study aimed to assess the impact of the use of closed incision negative pressure wound therapy (ciNPWT) after immediate breast reconstruction on the number of surgical-site complications, skin surface temperature, objective elastic and viscoelastic and subjective scar's quality to determine risk factors that could be considered as indications for prophylactic ciNPWT application.

NCT ID: NCT04796363 Active, not recruiting - Breast Cancer Clinical Trials

US Guided Erector Spinae Plane Block in Breast Cancer Surgery: Analgesia, Spread and Immunomodulation

Start date: November 25, 2020
Phase: N/A
Study type: Interventional

Prospective interventional study

NCT ID: NCT04666805 Active, not recruiting - Breast Cancer Clinical Trials

Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast

Start date: July 1, 2020
Phase:
Study type: Observational

This study will investigate the relationship between the endocrine therapy and the survival of patients with hormone receptor positive intraductal carcinoma of the breast, and the optimal duration of medication. This study will also analyze the risk factors of recurrence and metastasis of hormone receptor positive intraductal carcinoma of the breast and establish a prognosis model to further clarify the specific reasons for recurrence and metastasis, adverse reactions, and drug withdrawal in patients with hormone receptor positive intraductal carcinoma of the breast after endocrine therapy.

NCT ID: NCT04661982 Active, not recruiting - Breast Cancer Clinical Trials

Long Term Follow-Up in Patients With Stage 0-IIIC Breast Cancer

Start date: July 2009
Phase:
Study type: Observational

This trial studies long term follow-up care in patients with stage 0-IIIC breast cancer. Collecting feedback from breast cancer patients may help researchers to define comprehensive long term follow-up care for breast cancer survivors, better understand health-related quality of life and long-term complications in breast cancer survivors, and to increase the knowledge of the mechanisms by which a patient's own immune system attempts to combat breast cancer, and what factors may make this response more successful.

NCT ID: NCT04638712 Active, not recruiting - Breast Cancer Clinical Trials

Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer Patients

PROTECT-03
Start date: September 16, 2020
Phase: N/A
Study type: Interventional

This is an interventional, prospective and monocentric study. This study includes the evaluation before and after (neo)adjuvant therapy of : - one group of patients receiving anthracyclines and taxanes - a second group of patients receiving anthracyclines, taxanes and trastuzumab.

NCT ID: NCT04625621 Active, not recruiting - Breast Cancer Clinical Trials

Breast Reconstruction by Exclusive Lipomodulin : Feasibility, Evaluation of the Aesthetic Result and Quality of Life

EXCLUFAT
Start date: October 1, 2020
Phase:
Study type: Observational

Breast cancer is the leading female cancer in metropolitan France in terms of incidence and death. Among the therapeutic arsenal for the treatment of these cancers, surgery plays a very important role and even if a conservative treatment is possible in the majority of cases, there is still an indication for mastectomy in about 30% of cases. Currently, only 30% of women who have undergone a mastectomy choose reconstruction. The primary objective of breast reconstruction from a surgical point of view is to leave as few aesthetic and functional after-effects as possible while meeting the personal wishes of each woman according to her morphological, tissue and vascular characteristics. There are currently 2 major surgical procedures for breast reconstruction: breast implant reconstructions and autologous reconstructions. Breast reconstruction by prosthesis is the simplest and most widely used technique but, the controversies concerning implants with the PIP breast prostheses scandal in 2010 and more recently the anaplastic lymphoma scandal have tarnished the image of this type of reconstruction. Alternatives to breast implants have been developed: autologous reconstructions using first pedicled tissue flaps, then free flaps, techniques that allow a more natural, more satisfactory aesthetic result with an evolution that follows the patient's own morphology but requiring specific training in microsurgery and not without postoperative complications. Since 1999, the investigators have witnessed the evolution of another autologous technique, that of lipomodulin. Initially used to improve the results of reconstructions and the aesthetic sequelae of conservative treatments, it is now used as an exclusive reconstruction technique. Easily reproducible and offering several advantages, reconstruction by exclusive lipomodulin is increasingly appreciated by patients. However, this increasingly practiced technique presents specific problems and this is what the investigators want to evaluate in this study. The main objective of this study is to evaluate the practices within our establishment regarding breast reconstruction by exclusive lipomodulin in terms of feasibility. The secondary objectives are the evaluation of the cosmetic result and the quality of life of these patients after this type of reconstruction.

NCT ID: NCT04625517 Active, not recruiting - Breast Cancer Clinical Trials

Performance of Contrast-Enhanced Spectral Mammography to Assess Neoadjuvant Chemotherapy Response (CEDM)

Start date: January 22, 2020
Phase: Phase 4
Study type: Interventional

This study is designed to investigate the diagnostic accuracy of Contrast Enhanced Spectral Mammography (CEDM) in predicting early neoadjuvant therapy response and pathologic complete response (pCR) compared to mammography. Patients diagnosed with invasive breast cancer with available mammography and ultrasound imaging are eligible for the study. Eligible patients will be imaged at baseline (before initiation of neoadjuvant chemotherapy or endocrine therapy), early (2-4 cycles of neoadjuvant therapy) and late (after completion of neoadjuvant chemotherapy or endocrine therapy) timepoints with mammography. CEDM will be done within 2 weeks of the specified timepoint. Additionally, a survey of subject experience with CEDM and other pre-operative imaging will be collected after CEDM is performed.

NCT ID: NCT04551105 Active, not recruiting - Breast Cancer Clinical Trials

Evaluation of TaiHao Breast Ultrasound Diagnosis Software

Start date: August 15, 2020
Phase: N/A
Study type: Interventional

The BR-USCAD DS Module is a computer-assisted detection and diagnosis software based on a deep learning algorithm. This retrospective, fully-crossed, multi-reader, multi-case (MRMC) study aims to compare the performances of readers without and with the aid of the Breast Ultrasound Image Reviewed with Assistance of Computer-Assisted Detection and Diagnosis System (BR-USCAD DS) in interpreting breast ultrasound images of lesions.

NCT ID: NCT04517318 Active, not recruiting - Breast Cancer Clinical Trials

Treatment After Palbociclib-containing Regimens

Start date: August 15, 2017
Phase:
Study type: Observational

To evaluate the prescription patterns and treatment outcomes of subsequent therapies after progression on palbociclib in the real world.